World's First Probiotic for the Mouth and Throat

Research Studies

The Science Behind BLIS K12™

BLIS K12™ is naturally occurring, strain of the common oral bacteria called S. salivarius. BLIS Technologies Ltd has patented this unique strain and called it BLIS K12™.

research blis

Link To Keywords
PubMed.gov Streptococcus Salivarius k12
   

BLIS K12 Reference List of Peer Reviewed Studies and Book Chapters:

Researcher Year Country of Research Study Title & Publication
     

ORAL INFECTIONS

Tagg et al 2008 New Zealand

Streptococci as effector organisms for probiotic and

replacement therapy. Therapeutic Microbiology:

Probiotics and Other Therapies. Edited by Versalovic J & Wilson M. (American Society for Microbiology Press) Streptococci as effector organisms for probiotic and replacement therapy. Therapeutic Microbiology: Probiotics and Other Therapies. Edited by Versalovic J & Wilson M. (American Society for Microbiology Press) Streptococci as effector organisms for probiotic and replacement therapy. Therapeutic Microbiology: Probiotics and Other Therapies. Edited by Versalovic J & Wilson M. (American Society for Microbiology Press)

 
Horz et al. 2007 Germany Distribution and persistence of probiotic Streptococcus salivarius K12 in the human oral cavity as determined by real-time quantitative polymerase chain reaction. Oral Microbiol Immunol. 2007 Apr;22 (2):126-30.
Tagg et al. 2006 New Zealand Oral streptococcal BLIS: Heterogeneity of the effector molecules and potential role in the prevention of streptococcal infections, International Congress Series, 2006, Vol 128: 347-350
Tagg et al. 2004 New Zealand Prevention of streptococcal pharyngitis by anti-Streptococcus pyogenes bacteriocin-like inhibitory substances (BLIS) produced by Streptococcus salivarius. Indian J Med Res. 2004 May;119 Suppl:13-6.
Tagg et al. 2003 New Zealand

Bacterial replacement therapy: adapting 'germ warfare' to infection prevention. Trends in Biotechnology. 21(5): 217-23.

     

PERIODONTAL DISEASE

James & Tagg 1991 New Zealand The prevention of dental caries by BLIS-mediated inhibition of mutans streptococci. N Z Dent J. 1991 Jul;87(389):80-3.
     

UPPER RESPIRATORY TRACT INFECTIONS

Power et al. 2008 New Zealand Preliminary investigations of the colonisation of upper respiratory tract tissues of infants using a paediatric formulation of the oral probiotic Streptococcus salivarius K12. Eur J Clin Microbiol Infect Dis. 2008 Jun 17.
       

HALITOSIS

Burton et al. 2005 New Zealand The rationale and potential for the reduction of oral malodour using Streptococcus salivarius probiotics, Oral Diseases (2005) 11 (Suppl. 1), 29–31
Burton et al. 2006 New Zealand A preliminary study of the effect of probiotic Streptococcus salivarius K12 on oral malodour parameters, J Appl Microbiol. 2006 Apr; 100(4):754-64.
     

SAFETY

Burton et al. 2006 New Zealand Safety assessment of the oral cavity probiotic Streptococcus salivarius K12. Appl Environ Microbiol. 2006 Apr;72(4):3050-3.
       

IMMUNITY

Cosseau et al. 2008 Canada and United Kingdom The commensal Streptococcus salivarius K12 down-regulates the innate immune responses of human epithelial cells and promotes hostmicrobe homeostasis. Infection and Immunity, Sept. 2008, p. 4163–4175
       

OTITIS MEDIA

Tagg et al. 2003 New Zealand Bacteriocin-like inhibitory substance (BLIS) production by the normal flora of the nasopharynx: potential to protect against otitis media? J Med Microbiol. 2003 Sep;52(Pt 9):829-33.
Wescombe et al. 2006 New Zealand & Canada Megaplasmids encode differing combinations of lantibiotics in Streptococcus salivarius, Antonie Van Leeuwenhoek. 2006 Oct;90 (3):269-80
Tagg et al. 2003  New Zealand Bacterial replacement therapy: adapting ‘germ warfare’ to infection prevention, Trends Biotechnol. 2003 May;21 (5):217-23.
Heng et al. 2006 New Zealand The Diversity of bacteriocins produced by Grampositive bacteria. (Book Chapter) Evolution and Ecology of Bacteriocins. Springer New York, Editor: M Riley.
Hyink et al. 2007 New Zealand

Salivaricin A2 and the novel antibiotic salivaricin B, are encoded by adjacent loci on a 190 kb transmissible megaplasmid in the oral probiotic strain Streptococcus salivarius K12. Appl Environ Microbiol 73(4): 1107-13.

Wescombe et al. 2006 New Zealand Production of the lantibiotic salivaricin A and its variants by oral streptococci and use of a specific induction assay to detect their presence in human saliva. Appl Environ Microbiol. 2006 Feb;72(2):1459-66.
     

UPPER RESPIRATORY

Di Pierro et al 2015 Italy Oral use of Streptococcus salivarius K12 in children with secretory otitis media: preliminary results of a pilot, uncontrolled study. Int J Gen Med. 2015 Sep 15;8:303-8.
     

OTHER

Patras et al 2015 USA / New Zealand Streptococcus salivarius K12 Limits Group B Streptococcus Vaginal Colonization. Infect Immun. 2015 Sep;83(9):3438-44.
     

DENTAL HEALTH

Di Pierro et al 2015 Italy Cariogram outcome after 90 days of oral treatment with Streptococcus salivarius M18 in children at high risk for dental caries: results of a randomized, controlled study. Clin Cosmet Investig Dent. 2015 Oct 3;7:107-13.

Please wait...